Advertisement

POEMS syndrome: clinical update

  • Rachel Brown
  • Lionel Ginsberg
Open Access
Neurological Update

Abstract

POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, M-protein, skin changes) is a rare paraneoplastic syndrome, caused by a plasma cell proliferative disorder, which is most commonly lambda restricted. The neurological hallmark, which forms one of the mandatory criteria for diagnosis, is a subacute onset demyelinating neuropathy, which can be rapidly disabling and painful. A number of multi-system features are also characteristic of this disorder, and certainly not restricted to those included in its acronym, which though limited, remains a useful and memorable name, helping distinguish POEMS syndrome from other paraproteinaemic neuropathies. The discovery of vascular endothelial growth factor (VEGF) in association with POEMS syndrome has been extremely useful in aiding clinical diagnosis, and monitoring response to treatment, as well as helping understand the underlying mechanism of disease. Interestingly, however, treatment targeting VEGF has been disappointing, suggesting other disease mechanisms or inflammatory processes are also important. Current understanding of the pathogenesis of POEMS syndrome is outlined in detail in the accompanying article by Cerri et al. Here, we review the clinical features of POEMS syndrome, differential diagnosis and available treatment options, based on current literature.

Keywords

Neuropathy Paraproteinaemia Monoclonal gammopathy Vascular endothelial growth factor (VEGF) 

Introduction

The diagnosis of POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, M-protein, skin changes), based on the current Dispenzieri diagnostic criteria [1], requires the presence of both mandatory criteria (a polyneuropathy and a monoclonal plasma cell-proliferative disorder, almost always lambda restricted), and at least one major and one minor criterion (Table 1). POEMS syndrome differs from other paraproteinaemic and inflammatory neuropathies by its multi-organ involvement, thought to be caused by elevated pro-inflammatory and angiogenic cytokines. Multi-organ features extend beyond those included in its acronym, and not all features included in the acronym are required for diagnosis.

Table 1

Diagnostic criteria

Mandatory criteria

 Polyneuropathy

 Monoclonal plasmaproliferative disorder

Other major criteria

 Sclerotic bone lesions

 Castleman’s disease

 Elevated VEGF

Minor criteria

 Organomegaly

 Oedema

 Endocrinopathy

 Skin changes

 Papilloedema

 Thrombocytosis/Polycythaemia

Other symptoms and signs

 Clubbing

 Weight loss

 Hyperhidrosis

 Pulmonary hypertension

 Restrictive lung disease

 Thrombotic diathesis

 Low vitamin B12 level

 Diarrhoea

POEMS syndrome has a median age of onset in the sixth decade and a slight male preponderance [2]. Patients may present to one of a number of specialty clinics depending upon the initial symptoms. In the neurology clinic, patients typically describe a subacute, painful, distal neuropathy. If POEMS syndrome is suspected, a thorough systemic examination and timely organisation of relevant investigations are required to elicit all features that might aid diagnosis.

POEMS syndrome remains a rare disease and evidence for treatment is largely limited to retrospective cohort studies or case reports. Current treatment strategies all target the underlying plasma cell clone, with the exception of bevacizumab, a monoclonal antibody targeting vascular endothelial growth factor (VEGF), which has had disappointing results. Management can be complicated, and POEMS syndrome can be fatal. With the right treatment, however, prognosis in many patients can be very good. Joint specialty clinics, usually staffed by haematologists and neurologists, can be valuable.

Clinical features

Polyneuropathy

Clinical findings

Patients typically present with a subacute, distal, symmetrical, sensorimotor neuropathy, frequently painful, with allodynia and hyperpathia [3, 4]. Neuropathy is a common first clinical feature, and may be the only feature at first presentation [3, 5].

The lower limbs are affected earlier, and more severely, than the upper limbs [3, 6, 7]. Sensory symptoms usually precede motor symptoms [6]. Many patients quickly become wheelchair- or bed-bound due to weakness or pain. Clinical examination may reveal distal wasting, weakness and sensory loss affecting both large and small fibre sensory modalities [3].

Neurophysiology

Electrodiagnostic studies demonstrate a length-dependent sensorimotor neuropathy, typically demyelinating, but with axonal degeneration [5, 7]. Conduction block is not usually present [5, 7]. In motor studies, reduction in motor conduction velocity (MCV) is an early sign, however, patients often already have significant axonal loss at presentation [7]. Sensory studies show reduction of, or often absent, sensory nerve action potentials [3, 5].

POEMS syndrome is distinguishable from other polyneuropathies on electrodiagnostic studies, with some overlap. In a study of 51 patients with POEMS syndrome, 70% met the European Federation of Neurological Societies and Peripheral Nerve Society criteria for definite chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) [3]. Reduction in MCV is typically seen in similar proportions of patients with POEMS syndrome, CIDP and CMT1a [3, 8]. However, while distal motor latencies tend to be prolonged in POEMS syndrome, they are less prolonged (and less often) than in CIDP or CMT1a [3, 8]. This is thought to indicate that slowing in POEMS syndrome is more prominent in intermediate than distal segments, suggesting a potentially different disease pathogenesis from other inflammatory neuropathies [3, 5, 8, 9]. Conduction block is much more common in CIDP than POEMS syndrome [3, 8], and the discrepancy in severity between upper and lower limb axonal loss is more pronounced in POEMS syndrome [3, 8].

Neuropathology

Nerve biopsy can be used to support a diagnosis of POEMS syndrome, though in practice it is not essential, especially when other clinical and paraclinical findings already fulfil the diagnostic criteria. A number of pathological hallmarks for POEMS syndrome have been identified and are outlined in detail in the accompanying article by Cerri et al. Of all these features, the finding of regular uncompacted myelin lamellae (UML) in ≥ 1% of myelinated nerve fibres on electron microscopy, is thought to be highly specific for POEMS syndrome, though not 100% pathognomonic [10, 11].

Plasma cell dyscrasia

The plasma cell disorder underlying POEMS syndrome is typically IgA or IgG lambda restricted [12]. A paraprotein can be identified on serum protein electrophoresis and/or immunofixation in most patients, though in our own experience, and as noted in larger series [6, 12], some patients do not have a detectable paraprotein, even after serial testing. Demonstrating a plasma cell clone in these patients requires more extensive investigation.

Bone marrow biopsy

Patients with POEMS syndrome typically have few monoclonal plasma cells on iliac crest biopsies. In patients with localised disease, iliac crest biopsies can be normal [6, 12]. In a study of 87 patients at the Mayo clinic, the median percentage of plasma cells in 67 pre-treatment bone marrow specimens was < 5%, with monoclonal plasma cells detected in two-thirds [12]. A typical finding in around half of pre-treatment specimens was the presence of histologically reactive-appearing lymphoid aggregates containing mixed B- and T-cells, with a plasma cell rim, most commonly lambda restricted (though some polytypic), thought to be unique to POEMS syndrome. Other frequent findings included megakaryocyte hyperplasia and clustering, and atypical megakaryocyte appearances. Peripheral blood smears were normal.

Within osteosclerotic lesions, atypical plasma cells infiltrate normal marrow with sclerosis of the bony lamellae [6]. Bone marrow aspirates from osteosclerotic lesions in two patients, by Kulkarni et al., revealed high levels of plasmacytosis (> 10%), while more sclerotic lesions were hypo- or acellular [6].

Other major criteria

Castleman’s disease

Castleman’s disease (CD) is a rare heterogeneous lymph node disorder associated with high levels of interleukin-6 (IL-6) [13]. Patients with CD can have neuropathy, with or without POEMS syndrome. In a minority, CD co-exists with neuropathy and a POEMS-like syndrome, without evidence of a monoclonal plasma cell disorder. These patients are excluded in the current diagnostic criteria for POEMS syndrome as they do not fulfil the mandatory criteria, and are felt to have a different disease/pathogenesis [1]. The type and severity of neuropathy differs depending upon the presence or absence of POEMS syndrome or CD. Patients with CD and neuropathy without POEMS syndrome typically have a mild, painless, distal sensory neuropathy, while patients with POEMS syndrome +/- CD typically have a painful sensorimotor neuropathy, most severe in those without CD [14].

In a study of 113 patients with biopsy confirmed CD treated between 1948 and 2002, 18% met criteria for POEMS syndrome [15]. Conversely, in a study of 87 patients with POEMS syndrome, 10 had CD and 5 had CD-like features on lymph node biopsy [12]. Patients with POEMS syndrome mostly exhibit HHV8 negative multicentric CD (MCD) [12, 14, 15].

Overall survival is dependent on the presence or absence of CD, osteosclerotic lesions, and POEMS syndrome. In a Mayo clinic cohort, 5-year survival was very good in patients with unicentric CD (91%) or with MCD with osteosclerotic lesions and POEMS syndrome (90%), good in patients with MCD without POEMS syndrome (65%), and very poor in patients with MCD and POEMS syndrome without osteosclerotic bone lesions (27%) [15].

Sclerotic bone lesions

POEMS syndrome is associated with predominantly osteosclerotic bone lesions, which can have mixed sclerotic-lytic components, and are also referred to as osteosclerotic myeloma. Lesions are often small, and multiple; in a study of 28 patients undergoing chest and abdominal CT imaging, 68% of patients had multiple bone lesions, with 146 lesions identified in total, 97% reported as sclerotic, and 71% <10 mm in diameter [16]. Further imaging by 99mTc-HMDP bone scintigraphy enabled the pick-up of additional lesions in the skull and long bones, not in the field of view of CT, demonstrating a benefit from imaging the complete skeleton, and of using dual imaging modalities. 18F-FDG PET/CT imaging can also aid diagnosis and help identify lesions suitable for biopsy [17]. Lesions are commonly found in the pelvis, thoracic and lumbar vertebrae, and ribs, and also occur in the scapula, clavicle, sternum, skull and long bones [16, 17].

Vascular endothelial growth factor

Elevated VEGF is highly specific for POEMS syndrome (though not pathognomonic) and thought to be involved in the pathophysiology of systemic features including organomegaly and volume overload. Serum VEGF levels reflect disease activity, falling with treatment and rising with disease progression or relapse. Monitoring VEGF levels may be useful as a disease prognostic marker; Misawa et al. showed that reduction in serum VEGF levels to within the normal range by 6-months post-treatment was associated with longer relapse-free survival and better outcomes [18].

Minor criteria

Organomegaly

Clinical and radiological studies have shown that imaging, particularly CT, has higher sensitivity in identifying organomegaly compared to clinical examination [6, 19]. In a retrospective cohort of 29 patients diagnosed with POEMS syndrome in India between 1983 and 2009, all had organomegaly, including hepatomegaly (28/29), splenomegaly (21/29) and lymphadenopathy (7/29) [6]. The reporting of organomegaly is variable, however, and is lower in other cohorts [2].

Extravascular volume overload

Fluid overload may present peripherally or centrally. In a study of 91 patients undergoing 18FDG-PET CT, 46 had had serous cavity effusions, often affecting more than one cavity [17]. The four most common sites were pleural, pelvic, pericardial and abdominal.

Endocrinopathy

In a retrospective study of 64 patients with POEMS syndrome, 84% had endocrinopathy, 54% of whom had multiple endocrinopathies [20]. Hypogonadism was commonest, affecting 79% of men. Other endocrine abnormalities described include thyroid dysfunction, abnormal calcium metabolism, glucose intolerance, diabetes, hyperprolactinemia, gynaecomastia, and less commonly adrenal insufficiency [20, 21, 22]. For diagnostic purposes, diabetes and thyroid disease alone are insufficient evidence of endocrinopathy, given the high incidence of both conditions separately in the general adult population [1].

Skin changes

Skin changes are reported in as many as 90–100% of patients [6, 23, 24]. In a study of 107 patients with POEMS syndrome, patients had an average of 3 types of skin changes [23]. Hyperpigmentation and haemangiomas are the commonest findings [23, 24]. Other skin changes include skin thickening, hypertrichosis, acquired facial lipoatrophy, and infiltrated livedo reticularis with necrosis [23, 24]. Vascular-type skin changes can include acrocyanosis, flushing, rubor, hyperaemia and Raynaud’s phenomenon [23, 24]. Nail changes include leukonychia and clubbing. Skin ulceration related to calciphylaxis can occur [25]. There is a significant association between the presence of skin changes and abnormal pulmonary function tests, suggesting these patients be meticulously screened for respiratory complications [23].

Papilloedema

Optic disc swelling is often visible on bedside direct ophthalmoscopy, with detection aided by formal ophthalmology assessment and optical coherence tomography (OCT). In a retrospective study of 33 patients, 52% had bilateral disc swelling [26]. In some patients with disc swelling, raised CSF opening pressures have been described, though this is unlikely to be the only causative factor [26]. Elevated CSF protein, often linked to optic disc swelling in other inflammatory neuropathies, is present in POEMS syndrome [6]. Increased vascular permeability secondary to elevated VEGF may also be important. In a study of 17 patients with POEMS syndrome, serum VEGF concentrations were significantly higher in patients with disc swelling compared to those without, and there was a positive correlation between serum VEGF levels and peripapillary retinal thickness on OCT [27]. None of the studied patients had elevated CSF opening pressures. Improvement of disc swelling has been shown to correlate with fall in VEGF concentrations [26].

Thrombocytosis and Polycythaemia

Thrombcytosis and polycythaemia commonly occur, however, testing for JAK2 mutation is typically negative [12].

Other described associations

Pulmonary symptoms

Pulmonary hypertension (PH) was found in 27% of a cohort of 154 patients with POEMS syndrome [28]. Unlike with primary PH, PH in POEMS syndrome tends to follow a less progressive, less severe course, and improve with treatment [28, 29]. In a different cohort, 28% of 137 patients had chest symptoms within 2 years of diagnosis [30]. The presence of respiratory muscle weakness is associated with a poorer survival outcome [30].

CNS involvement

In a study of 11 patients with POEMS syndrome, 9 had asymptomatic cranial pachymeningeal thickening on gadolinium-enhanced MRI [31]. Meningeal biopsy in two patients showed meningothelial cell proliferation with vascular changes including neovascularisation, and narrowing/occlusion of arterioles due to thickening of the media and endothelial hyperplasia. The role of VEGF was suggested by immunohistochemical staining for VEGF and VEGFR2.

Arterial vascular disease

Cardio- and cerebrovascular risk may be increased in POEMS syndrome. In a cohort of 90 patients, the estimated 5-year ischaemic stroke risk was 13.4% [32]. Risk factors included degree of thrombocytosis on presentation and presence of bone marrow plasmacytosis. There were no cases of stroke in patients with treated POEMS syndrome and the authors suggested that treating the underlying syndrome was probably the best mechanism for reducing arterial risk.

Renal disease

Renal dysfunction has been documented to varying degrees. In a retrospective study of 299 patients with POEMS syndrome from China, 67 had renal impairment, mostly of moderate degree [33]. Microhaematuria and significant proteinuria were present in 29 and 17 patients, respectively. In other cohorts, the incidence of renal dysfunction is lower [1]. In the Chinese cohort, renal function improved with treatment in 66%. Early death and reduced overall survival were significantly likelier in patients who had severe renal dysfunction (estimated glomerular filtration rate < 30 ml/min/1.73 m2) at baseline. Pathological findings on renal biopsy, presumably secondary to the effects of VEGF and pro-inflammatory cytokines, include glomerular enlargement, with endothelial and mesangial cell proliferation and small artery vasculopathy [33, 34].

Patient evaluation and investigations

When POEMS syndrome is suspected, a detailed history and systems examination are essential. Recommended investigations are listed in Table 2. CSF examination usually reveals an elevated protein in the range of 1–2 g/L but a normal cell count [6].

Table 2

Useful investigations

Laboratory studies

 Full blood count

 Clotting profile

 Renal and liver function tests

 Endocrinopathy screen

 Paraprotein screen inc. serum protein electrophoresis, immunofixation, serum free light chains (+ urine Bence Jones proteins)

 VEGF level

 Cerebrospinal fluid analysis

Imaging

 99mTc-HMDP bone scintigraphy

 FDG-PET CT

Histology

 Iliac crest bone marrow aspirate/biopsy

 ± lymph node biopsy

 Nerve biopsy (if haematological studies inconclusive)

Differential diagnosis

Chronic inflammatory demyelinating polyradiculoneuropathy

CIDP is an inflammatory, proximal and distal sensory-motor neuropathy, with demyelinating features. Differences between CIDP and POEMS syndrome are listed in Table 3 [3]. Unlike POEMS syndrome, CIDP usually responds well to monotherapy with intravenous immunoglobulin (IVIg) or steroids [35].

Table 3

POEMS vs CIDP [3, 8, 36, 37]

 

POEMS

CIDP

Clinical findings

Distal and proximal sensory and motor neuropathy

Distal and proximal sensory and motor neuropathy

 

Often painful

Painless

Neurophysiology

Demyelinating polyradiculoneuropathy with axonal loss

Demyelinating polyradiculoneuropathy

Distal motor latency

Prolonged

More prolonged than POEMS

Conduction velocities

Decreased (demyelinating range)

Similarly decreased (demyelinating range)

Compound muscle action potentials

Significantly attenuated, often absent

Less severely attenuated

Lower limb vs upper limb discrepancy

Significantly worse in lower limbs compared to upper limbs

Less discrepancy between upper and lower limbs

Distribution

Intermediate nerve segments most affected

Proximal and terminal nerve segments most affected

Neuropathology

More severe axonal loss

 
 

Diffuse loss of myelinated fibres

Multifocal loss of myelinated fibres

 

Degree of epineurial inflammation

Endoneurial mononuclear cell infiltration and degree of epineurial inflammation

 

Epineurial vascular proliferation

 
 

Uncompacted myelin lamellae > 1%

Onion bulb formation

Biomarkers

Elevated VEGF

Antibodies to paranodal proteins and gangliosides in a minority of cases

Monoclonal gammopathy of undetermined significance (MGUS)

MGUS is a pre-malignant plasma cell disorder, with IgM, non-IgM or light chain subgroups, which can transform into Waldenstrom’s macroglobulinaemia (WM), myeloma or AL amyloidosis [38]. There is a male predominance, and age of onset is typically higher than for POEMS syndrome [9]. Neuropathy is not required for diagnosis. Unlike POEMS syndrome, neuropathy, when present, is mostly associated with IgM paraproteins, usually IgM kappa [9] and many patients have antibodies targeting myelin-associated glycoprotein (MAG). The neuropathy in these patients is clinically different from POEMS syndrome: typically sensory and painless, often with sensory ataxia and tremor [39]. Progression is slow, and neuropathy can be mild for many years. A watch-and-wait approach is commonly adopted, with decision to treat based on severity and rate of progression.

Waldenstroms macroglobulinaemia (WM)

WM is a malignant plasma cell dyscrasia, with an IgM paraprotein and > 10% infiltration of lymphoplasmacytic cells in the bone marrow [40]. It is usually indolent but can transform into a high-grade lymphoma. Like MGUS, there is a male predominance, and age of onset is usually older than POEMS syndrome. Around half of patients may have a symptomatic neuropathy, typically a distal sensory neuropathy, clinically similar to MGUS, but with more axonal features on electrodiagnostic testing [41, 42]. Systemic symptoms can occur due to very high paraprotein levels and associated hyperviscosity. Systemic signs in WM can include hepatosplenomegaly, lymphadenopathy and anaemia. Treatment involves a rituximab-based chemotherapy regime, monitoring for hyperviscosity, and supportive treatment [40, 43].

Myeloma

Myeloma is a malignant plasma cell disorder of bone marrow, causing osteolytic bone lesions and end-organ damage including anaemia, hypercalcaemia and renal failure [44]. The percentage of malignant plasma cells in bone marrow is much higher than in POEMS syndrome. Neuropathy attributable to disease is less common in myeloma than MGUS and WM and may often be attributable to chemotherapy rather than the disease process. Neuropathy is typically axonal but more heterogeneous than in MGUS, WM or POEMS syndrome. Treatment strategies target the plasma cell clone [44]. Most of the treatments for POEMS syndrome were first used in myeloma.

Immunoglobulin light chain (AL) amyloidosis

AL amyloidosis is an acquired disorder caused by monoclonal, non-malignant plasma cells producing immunoglobulin light chains, most often lambda, which misfold into insoluble beta-pleated sheets and deposit in the tissues [45]. Histopathological identification of amyloid is achieved using Congo red staining with apple-green birefringence under polarised light. Like POEMS syndrome, AL amyloidosis has a number of characteristic systemic complications, though these are secondary to AL amyloid deposition. The complications include cardiomyopathy, hepatomegaly, nephrotic syndrome, fatigue and weight loss. Around a quarter of patients have polyneuropathy, which is typically painful like in POEMS [46]. In contrast, however, amyloid neuropathies are usually axonal and feature prominent autonomic involvement [46]. Amyloid is characteristically absent in nerve and bone marrow biopsies in patients with POEMS syndrome [6]. The prognosis of AL amyloidosis without treatment is poor, especially in patients with cardiac involvement [45]. Treatment options are similar to POEMS syndrome, and include autologous stem cell transplant (ASCT) or chemotherapy [45, 47].

CANOMAD

Chronic Ataxic Neuropathy with Ophthalmoplegia, M-protein, Cold Agglutinins and Disialosyl antibodies (CANOMAD), is an antibody-associated neuropathy, caused by IgM antibodies targeting disialylated and polysialylated gangliosides, including GD1b, GD3, GT1b and GQ1b [48]. Light chains may be kappa or lambda restricted or both [48]. The origin of the IgM antibodies is unclear; only some cases are reported to have an underlying plasma cell dyscrasia. Clonal B-cell infiltration in cranial and peripheral nerves and nerve roots has been described in one case [49]. Similar to POEMS syndrome, there is a male predominance and age of onset is typically in the 6th decade [48]. The neuropathy is often severe, but tends to be more slowly progressive than in POEMS syndrome, and predominantly sensory, often with a disabling sensory ataxia, and either demyelinating or axonal features on electrodiagnostic testing [48, 50].

Management

Evidence for treatment in POEMS syndrome is largely limited to retrospective cohort studies, with only one randomised controlled trial (RCT) to date [51, 52]. IVIg or steroid monotherapy, commonly used in other inflammatory neuropathies, does not produce lasting benefit.

The current suggested treatment algorithm recommends localised radiotherapy for patients with localised disease, defined as up to 3 discrete bone lesions and no evidence of clonal plasma cells on iliac crest biopsy, or systemic treatment in patients with diffuse disease, defined as > 3 bone lesions or clonal plasma cells on iliac crest biopsy [53]. Systemic treatment options include ASCT or chemotherapy. Supportive treatment for neurological disability and systemic symptoms should also be considered [52, 53].

Radiotherapy

In a retrospective study of 146 patients treated at the Mayo clinic, 38 patients received radiotherapy as a first definitive treatment for POEMS syndrome [54]. 54/66 of identified bone lesions were irradiated. Overall survival was 97% at 4 years, including patients requiring salvage therapy, suggesting that even in patients where radiotherapy fails to prevent progression, trialling it first line may not negatively affect survival, and may prevent unnecessary systemic therapy in responders. Response to treatment was mixed: event free survival was 52% at 4 years, 47% had clinical improvement, and 48% required salvage treatment for poor response, progression or relapse. Patients with better haematological responses had lower risk of treatment failure. A retrospective study of 33 patients, treated in Seoul, also showed that radiotherapy was effective in improving clinical symptoms of POEMS syndrome in some patients, either alone or in combination with chemotherapy [55].

Alkylating chemotherapy agents

Melphalan can be effective with or without ASCT. In a single centre prospective study of 31 patients using a 12-cycle treatment regime of melphalan and dexamethasone, complete and partial haematological responses were achieved in 38.7% and 41.9% patients, respectively [56]. All had improvement in neurological symptoms. There were no treatment-related deaths. It was suggested that melphalan with dexamethasone was safe and effective, without the cost and treatment-related morbidity of ASCT, but longer term conclusions were limited by the short follow-up period (median 21 months).

Autologous stem cell transplant

Two large retrospective cohort studies support the use of ASCT in POEMS syndrome [57, 58]. Further studies are needed to compare relative risks and benefits of ASCT to other systemic treatments [57]. Though modifications to the process of ASCT have been made, significant risks remain, including engraftment syndrome, chemotherapy-associated risks, graft failure, pancytopaenia, serious infection, and death.

The largest cohorts receiving ASCT, from Europe (127 patients) and the Mayo clinic (59 patients), reported a similar 5-year progression free survival of 74% and 75%, with patients followed up for a median 48 months and 45 months, respectively [57, 58]. Early responses included improvement in VEGF levels and systemic features such as volume overload [57]. In patients who progressed in the Mayo group, median time to progression was 43 months. Most relapses were radiological or VEGF-related, without clinical symptoms. Patients who progressed were still felt to have benefitted from ASCT, and most responded well to second line therapy or observation. There were 13 and 3 deaths in the European and Mayo cohorts, respectively.

Neurological symptoms have been shown to improve post-ASCT. In a study of 60 patients followed up over a median 61 months, wheelchair use improved from 45 to 0% post-transplant and there was a reduction in the number of patients requiring walking aids and ankle–foot orthoses [59].

Thalidomide and lenalidomide

In the first RCT in POEMS syndrome, 25 patients eligible for systemic therapy but not ASCT, were randomised to either thalidomide + dexamethasone or placebo + dexamethasone for 24 weeks, before proceeding to a 48-month open-label safety study where all patients received thalidomide [51]. At 24-weeks, reduction rate of VEGF (the primary endpoint) was significantly greater in the treatment group. Motor outcome and two SF-36 quality of life scores were also significantly improved in the treatment groups, but other secondary outcome measures were not. A new sensory neuropathy was found in 23% of patients in the open-label group, likely thalidomide-related, however, overall nerve function, particularly motor function, improved. Mild bradycardia was common. Overall, despite the short trial period, it was concluded that thalidomide was a safe and effective treatment for POEMS syndrome.

Lenalidomide is structurally similar to thalidomide, but less neurotoxic. Two recent prospective studies, a number of small retrospective studies and a pooled analysis study have all shown it to be effective in POEMS syndrome, as either first- or second-line therapy [60, 61, 62, 63, 64, 65].

Bortezomib

Bortezomib (Velcade) is a reversible proteosome inhibitor and approved by NICE for use with dexamathasone ± thalidomide in myeloma and untreated mantle cell lymphoma. He et al. studied 20 patients, newly diagnosed with POEMS syndrome between Dec 2014 and May 2016, given 3–6 cycles of induction therapy with reduced dose bortezomib, cyclophosphamide and dexamethasone [66]. Of those whose haematological response could be assessed, 7 showed complete response, 6 partial response and 4 had stable disease. Despite concerns about bortezomib causing peripheral neuropathy, no patient had worsening neurology and 19/20 had improvement in ONLS (Overall Neuropathy Limitations Scale) of at least 1 point. Systemic features also improved. No deaths or disease progression were seen during the follow-up period, though limited to 11 months.

Therapies targeting VEGF

Bevacizumab is a monoclonal antibody targeting VEGF. A number of small studies and case reports have shown mixed results with bevacizumab, including treatment failure (except VEGF response), and worsening of disease leading to death [67, 68, 69, 70]. Some case studies have shown benefit, though these have been limited by short or unclear follow-up periods, and bevacizumab has been used following, or in addition to other treatments including cyclophosphamide with dexamethasone [68, 71]. A small number of studies have suggested that short-term use of bevacizumab may be helpful as a bridge to definitive treatment such as ASCT, either alone or with other treatment such as thalidomide [72, 73]. At this stage, the role of bevacizumab is unclear, and better understanding of the pathophysiology of POEMS syndrome is required before it can be recommended.

Follow-up and outcomes

Post-treatment, prognosis in POEMS syndrome is good; in a study of 291 patients treated at the Mayo clinic between 1974 and 2014, 10-year overall survival was 62%, with younger age, albumin > 3.2 g/dL and complete haematological response to treatment all associated with better outcomes [74]. In an overlapping cohort, 5-year progression-free survival was 58%, with failure to achieve complete haematological response after first-line treatment the main predictor of relapse or progression [75]. Even in patients who relapsed, however, prognosis was good: 92% of patients responded to second line treatment, and most who relapsed again responded to further treatment. Given the risk of relapse, close follow-up of clinical, radiological and biochemical parameters, is essential.

Conclusions

POEMS syndrome is a rare, but treatable cause of neuropathy. Further work is required to establish its exact underlying pathophysiology. Current treatment approaches afford good prognosis. Moving forward, randomised-controlled studies, though difficult given the rarity of POEMS syndrome, and the development of prognostic tools, will be important in establishing individualised approaches to patient care.

Notes

Compliance with ethical standards

Conflicts of interest

Both authors declare that they have no conflict of interest.

References

  1. 1.
    Dispenzieri A (2017) POEMS syndrome: 2017 Update on diagnosis, risk stratification, and management. Am J Hematol 92:814–829CrossRefGoogle Scholar
  2. 2.
    Dispenzieri A et al (2003) POEMS syndrome: Definitions and long-term outcome. Blood 101:2496–2506CrossRefGoogle Scholar
  3. 3.
    Nasu S et al (2012) Different neurological and physiological profiles in POEMS syndrome and chronic inflammatory demyelinating polyneuropathy. J Neurol Neurosurg Psychiatry 83:476–479CrossRefGoogle Scholar
  4. 4.
    Koike H et al (2008) Neuropathic pain correlates with myelinated fibre loss and cytokine profile in POEMS syndrome. J Neurol Neurosurg Psychiatry 79:1171–1179CrossRefGoogle Scholar
  5. 5.
    Min JH, Hong YH, Lee K (2005) W. Electrophysiological features of patients with POEMS syndrome. Clin Neurophysiol 116:965–968CrossRefGoogle Scholar
  6. 6.
    Kulkarni GB et al (2011) Clinicopathological profile of polyneuropathy, organomegaly, endocrinopathy, M protein and skin changes (POEMS) syndrome. J Clin Neurosci 18:356–360CrossRefGoogle Scholar
  7. 7.
    Liu M et al (2015) Motor nerve conduction study and muscle strength in newly diagnosed poems syndrome. Muscle Nerve 51:19–23CrossRefGoogle Scholar
  8. 8.
    Sung JY, Kuwabara S, Ogawara K, Kanai K, Hattori T (2002) Patterns of nerve conduction abnormalities in POEMS syndrome. Muscle Nerve 26:189–193CrossRefGoogle Scholar
  9. 9.
    Kim H et al (2017) Electrophysiologic features of POEMS syndrome compared with MGUS-related neuropathy. Muscle Nerve 56:E73–E77CrossRefGoogle Scholar
  10. 10.
    Vital C et al (2003) Uncompacted myelin lamellae in peripheral nerve biopsy. Ultrastruct Pathol 27:1–5CrossRefGoogle Scholar
  11. 11.
    Vital C et al (2003) Crow-Fukase (POEMS) syndrome: a study of peripheral nerve biopsy in five new cases. J Peripher Nerv Syst 8:136–144CrossRefGoogle Scholar
  12. 12.
    Dao LN et al (2011) Bone marrow histopathology in POEMS syndrome: a distinctive combination of plasma cell, lymphoid, and myeloid findings in 87 patients. Blood 117:6438–6444CrossRefGoogle Scholar
  13. 13.
    Haap M, Wiefels J, Horger M, Hoyer A, Müssig K (2018) Clinical, laboratory and imaging findings in Castleman’s disease—the subtype decides. Blood Rev 32:225–234CrossRefGoogle Scholar
  14. 14.
    Naddaf E, Dispenzieri A, Mandrekar J, Mauermann ML (2016) Clinical spectrum of Castleman disease—associated neuropathy. Neurology 87:2457–2462CrossRefGoogle Scholar
  15. 15.
    Dispenzieri A et al (2012) The clinical spectrum of Castleman’s disease. Am J Hematol 87:997–1002CrossRefGoogle Scholar
  16. 16.
    Shibuya K et al (2011) Detection of bone lesions by CT in POEMS syndrome. Intern Med 50:1393–1396CrossRefGoogle Scholar
  17. 17.
    Pan Q, Li J, Li F, Zhou D, Zhu Z (2015) Characterizing POEMS Syndrome with 18F-FDG PET/CT. J Nucl Med 56:1334–1337CrossRefGoogle Scholar
  18. 18.
    Misawa S et al (2015) Vascular endothelial growth factor as a predictive marker for POEMS syndrome treatment response: Retrospective cohort study. BMJ Open 5:1–7CrossRefGoogle Scholar
  19. 19.
    Shi X et al (2016) CT characteristics in 24 patients with POEMS syndrome. Acta radiol 57:51–57CrossRefGoogle Scholar
  20. 20.
    Gandhi GY et al (2007) Endocrinopathy in POEMS syndrome: the Mayo Clinic experience. Mayo Clin. Proc 82:836–842CrossRefGoogle Scholar
  21. 21.
    Dun X-Y, Zhou F, Xi H, Yuan Z-G, Hou J (2009) Thyroid function and its clinical significance in POEMS syndrome. Leuk Lymphoma 50:2013–2016CrossRefGoogle Scholar
  22. 22.
    Marchand M, Haroche J, Touraine P, Courtillot C (2017) Atteintes endocriniennes dans le POEMS syndrome: conséquences incomprises d’un syndrome paranéoplasique rare. Ann Endocrinol (Paris) 78:190–194CrossRefGoogle Scholar
  23. 23.
    Miest RYN, Comfere NI, Dispenzieri A, Lohse CM, el-Azhary RA (2013) Cutaneous manifestations in patients with POEMS syndrome. Int J Dermatol 52:1349–1356CrossRefGoogle Scholar
  24. 24.
    Barete S et al (2010) Skin manifestations and vascular endothelial growth factor levels in POEMS syndrome: impact of autologous hematopoietic stem cell transplantation. Arch Dermatol 146:615–623CrossRefGoogle Scholar
  25. 25.
    Araki N et al (2016) POEMS syndrome and calciphylaxis: an unrecognized cause of abnormal small vessel calcification Rare skin diseases. Orphanet J Rare Dis 11:1–7CrossRefGoogle Scholar
  26. 26.
    Kaushik M, Pulido JS, Abreu R, Amselem L, Dispenzieri A (2011) Ocular findings in patients with polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes syndrome. Ophthalmology 118:778–782CrossRefGoogle Scholar
  27. 27.
    Yokouchi H et al (2016) Correlation between peripapillary retinal thickness and serum level of vascular endothelial growth factor in patients with POEMS syndrome. Br J Ophthalmol 100:897–901CrossRefGoogle Scholar
  28. 28.
    Li J et al (2013) Pulmonary hypertension in POEMS syndrome. Haematologica 98:393–398CrossRefGoogle Scholar
  29. 29.
    Lesprit P et al (1998) Pulmonary hypertension in POEMS syndrome: a new feature mediated by cytokines. Am J Respir Crit Care Med 157:907–911CrossRefGoogle Scholar
  30. 30.
    Allam JS, Kennedy CC, Aksamit TR, Dispenzieri A (2008) Pulmonary manifestations in patients with POEMS syndrome: a retrospective review of 137 patients. Chest 133:969–974CrossRefGoogle Scholar
  31. 31.
    Briani C et al (2012) Pachymeningeal involvement in POEMS syndrome: MRI and histopathological study. J Neurol Neurosurg Psychiatry 83:33–37CrossRefGoogle Scholar
  32. 32.
    Dupont SA, Dispenzieri A, Mauermann ML, Rabinstein AA, Brown RD (2009) Cerebral infarction in POEMS syndrome: Incidence, risk factors, and imaging characteristics. Neurology 73:1308–1312CrossRefGoogle Scholar
  33. 33.
    Ye W et al (2016) Renal impairment in patients with polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy and skin changes syndrome: Incidence, treatment and outcome. Nephrol Dial Transpl 31:275–283CrossRefGoogle Scholar
  34. 34.
    Nakamoto Y, Imai H, Yasuda T, Wakui H, Miura AB (1999) A spectrum of clinicopathological features of nephropathy associated with POEMS syndrome. Nephrol Dial Transpl 14:2370–2386CrossRefGoogle Scholar
  35. 35.
    Kuwabara S et al (2017) Intravenous immunoglobulin for maintenance treatment of chronic inflammatory demyelinating polyneuropathy: A multicentre, open-label, 52-week phase III trial. J Neurol Neurosurg Psychiatry 88:832–838CrossRefGoogle Scholar
  36. 36.
    Piccione EA et al (2016) Nerve pathologic features differentiate POEMS syndrome from CIDP. Acta Neuropathol Commun 4:116CrossRefGoogle Scholar
  37. 37.
    Burnor E et al (2017) Neurofascin antibodies in autoimmune, genetic, and idiopathic neuropathies. Neurology.  https://doi.org/10.1212/WNL.0000000000004773 CrossRefPubMedGoogle Scholar
  38. 38.
    Chaudhry HM, Mauermann ML, Rajkumar SV (2017) Monoclonal gammopathy–associated peripheral neuropathy: diagnosis and management. Mayo Clin. Proc 92:838–850CrossRefGoogle Scholar
  39. 39.
    Svahn J et al (2018) Anti-MAG antibodies in 202 patients: clinicopathological and therapeutic features. J Neurol Neurosurg Psychiatry 89:499–505CrossRefGoogle Scholar
  40. 40.
    Gertz MA (2017) Waldenström macroglobulinemia 2017 update on diagnosis, risk stratification, and management. Am J Hematol 92:209–217CrossRefGoogle Scholar
  41. 41.
    Levine T et al (2006) Peripheral neuropathies in Waldenström’s macroglobulinaemia. J Neurol Neurosurg Psychiatry 77:224–228CrossRefGoogle Scholar
  42. 42.
    Klein CJ et al (2011) The Neuropathies of Waldenström’s Macroglobulinemia (WM) and IgM-MGUS. Can J Neurol Sci 38:289–295CrossRefGoogle Scholar
  43. 43.
    Owen RG et al (2014) Guidelines on the diagnosis and management of Waldenström macroglobulinaemia. Br J Haematol 165:316–333CrossRefGoogle Scholar
  44. 44.
    Rajkumar SV (2016) Multiple myeloma 2016 update on diagnosis, risk-stratification, and management. Am J Hematol 91:719–734CrossRefGoogle Scholar
  45. 45.
    Gertz MA (2016) Immunoglobulin light chain amyloidosis: 2016 update on diagnosis, prognosis, and treatment. Am J Hematol 91:947–956CrossRefGoogle Scholar
  46. 46.
    Matsuda M et al (2011) Peripheral nerve involvement in primary systemic AL amyloidosis: a clinical and electrophysiological study. Eur J Neurol 18:604–610CrossRefGoogle Scholar
  47. 47.
    Dingli D et al (2010) Stem cell transplantation in patients with autonomic neuropathy due to primary (AL) amyloidosis. Neurology 74:913–918CrossRefGoogle Scholar
  48. 48.
    Willison HJ et al (2001) The clinical and laboratory features of chronic sensory ataxic neuropathy with anti-disialosyl IgM antibodies. Brain 124:1968–1977CrossRefGoogle Scholar
  49. 49.
    McKelvie PA, Gates PC, Day T (2013) Canomad report of a case with a 40-year history and autopsy. Is this a sensory ganglionopathy with neuromuscular junction blockade? Muscle Nerve 48:599–603CrossRefGoogle Scholar
  50. 50.
    Kam C et al (2011) CANOMAD presenting without ophthalmoplegia and responding to intravenous immunoglobulin. Muscle Nerve 44:829–833CrossRefGoogle Scholar
  51. 51.
    Misawa S et al (2016) Safety and efficacy of thalidomide in patients with POEMS syndrome: a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol 15:1129–1137CrossRefGoogle Scholar
  52. 52.
    Kuwabara S, Dispenzieri A, Arimura K, Misawa S, Nakaseko C (2012) Treatment for POEMS (polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes) syndrome. Cochrane Database Syst Rev.  https://doi.org/10.1002/14651858.CD006828.pub3 CrossRefPubMedGoogle Scholar
  53. 53.
    Dispenzieri A (2012) How I treat POEMS syndrome. Blood 119:5650–5658CrossRefGoogle Scholar
  54. 54.
    Humeniuk MS et al (2013) Outcomes of patients with POEMS syndrome treated initially with radiation. Blood 122:68–73CrossRefGoogle Scholar
  55. 55.
    Suh Y-G et al (2014) The role of radiotherapy in the management of POEMS syndrome. Radiat Oncol 9:265CrossRefGoogle Scholar
  56. 56.
    Li J et al (2011) Combination of melphalan and dexamethasone for patients with newly diagnosed POEMS syndrome. Blood 117:6445–6449CrossRefGoogle Scholar
  57. 57.
    D’Souza A et al (2012) Long-term outcomes after autologous stem cell transplantation for patients with POEMS syndrome (Osteosclerotic myeloma): a single-center experience. Blood 120:56–62CrossRefGoogle Scholar
  58. 58.
    Cook G et al (2017) High-dose therapy and autologous stem cell transplantation in patients with poems syndrome: a retrospective study of the plasma cell disorder sub-committee of the chronic malignancy working party of the European society for blood & marrow transplantation. Haematologica 102:160–167CrossRefGoogle Scholar
  59. 59.
    Karam C et al (2015) Polyneuropathy improvement following autologous stem cell transplantation for POEMS syndrome. Neurology 84:1981–1987CrossRefGoogle Scholar
  60. 60.
    Li J et al (2018) A prospective phase II study of low dose lenalidomide plus dexamethasone in patients with newly diagnosed polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes (POEMS) syndrome. Am J Hematol 93:803–809CrossRefGoogle Scholar
  61. 61.
    Nozza A et al (2017) Lenalidomide and dexamethasone in patients with POEMS syndrome: results of a prospective, open-label trial. Br J Haematol 179:748–755CrossRefGoogle Scholar
  62. 62.
    Lestang E et al (2015) Lenalidomide as frontline therapy in polyneuropathy, organomegaly, endocrinopathy, monoclonal protein and skin changes syndrome: a retrospective case series of eight patients. Leuk Lymphoma 56:1895–1896CrossRefGoogle Scholar
  63. 63.
    Cai Q-Q et al (2015) Efficacy and safety of low-dose lenalidomide plus dexamethasone in patients with relapsed or refractory POEMS syndrome. Eur J Haematol 95:325–330CrossRefGoogle Scholar
  64. 64.
    Royer B et al (2013) Efficacy of lenalidomide in POEMS syndrome: a retrospective study of 20 patients. Am J Hematol 88:207–212CrossRefGoogle Scholar
  65. 65.
    Zagouri F et al (2014) Lenalidomide in patients with POEMS syndrome: a systematic review and pooled analysis. Leuk Lymphoma 55:2018–2023CrossRefGoogle Scholar
  66. 66.
    He H, Fu W, Du J, Jiang H, Hou J (2018) Successful treatment of newly diagnosed POEMS syndrome with reduced-dose bortezomib based regimen. Br J Haematol 181:126–128CrossRefGoogle Scholar
  67. 67.
    Sekiguchi Y et al (2013) Ambiguous effects of anti-VEGF monoclonal antibody (bevacizumab) for POEMS syndrome. J Neurol Neurosurg Psychiatry 84:1346–1348CrossRefGoogle Scholar
  68. 68.
    Straume O et al (2006) Bevacizumab therapy for POEMS syndrome. Blood 107:4972–4973CrossRefGoogle Scholar
  69. 69.
    Perfetti V et al (2013) Bevacizumab treatment followed by maintenance in life-threatening POEMS syndrome. Ann Hematol 92:1133–1134CrossRefGoogle Scholar
  70. 70.
    Guitard J, Pillet A, Soubrier M, Modesto A, Chauveau D (2009) Polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, skin changes (POEMS) syndrome refractory to complete serum vascular endothelial growth factor (VEGF) blockade: Insights from sequential VEGF monitoring. NDT Plus 2:357–359PubMedPubMedCentralGoogle Scholar
  71. 71.
    Badros A et al (2005) Bevacizumab therapy for POEMS syndrome. Blood 106:1135CrossRefGoogle Scholar
  72. 72.
    Dietrich P-Y, Duchosal MA (2007) Bevacizumab therapy before autologous stem-cell transplantation for POEMS syndrome. Ann Oncol 19:595–595CrossRefGoogle Scholar
  73. 73.
    Ohwada C et al (2009) Successful combination treatment with bevacizumab, thalidomide and autologous PBSC for severe POEMS syndrome. Bone Marrow Transpl 43:739–740CrossRefGoogle Scholar
  74. 74.
    Kourelis TV et al (2016) Long-term outcome of patients with POEMS syndrome: An update of the Mayo Clinic experience. Am J Hematol 91:585–589CrossRefGoogle Scholar
  75. 75.
    Kourelis TV et al (2016) Risk factors for and outcomes of patients with POEMS syndrome who experience progression after first-line treatment. Leukemia 30:1079–1085CrossRefGoogle Scholar

Copyright information

© The Author(s) 2018

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Authors and Affiliations

  1. 1.Department of NeurologyRoyal Free HospitalLondonUK
  2. 2.Queen Square Institute of NeurologyUniversity College LondonLondonUK

Personalised recommendations